David Hinds

Director, Epidemiology and Real World Evidence
BioMarin Pharmaceutical, Inc.

Presentation(s):

• OC 21.5 - Comparative effectiveness of valoctocogene roxaparvovec and prophylactic factor VIII replacement estimated through propensity scoring

  Sunday, July 10, 2022
  3:45 PM – 4:00 PM

• PB0656 - Comparability of bleeding outcomes by prophylactic FVIII replacement intensity: A post-hoc analysis of a non-interventional study of men with severe hemophilia A

  Monday, July 11, 2022
  6:30 PM – 7:30 PM